Carcinoembryonic gene member 2 mRNA expression as a marker to detect circulating enterocytes in the blood of colorectal cancer patients

Surgery ◽  
2001 ◽  
Vol 129 (5) ◽  
pp. 587-594 ◽  
Author(s):  
Richard Douard ◽  
Valérie Le Maire ◽  
Philippe Wind ◽  
Jean-Patrick Sales ◽  
Frédéric Dumas ◽  
...  
2020 ◽  
Vol 75 ◽  
pp. 62-69 ◽  
Author(s):  
Pinelopi I. Artemaki ◽  
Aimilia D. Sklirou ◽  
Christos K. Kontos ◽  
Aikaterini-Anna Liosi ◽  
Despoina D. Gianniou ◽  
...  

2013 ◽  
Vol 1 (4) ◽  
pp. 668-674 ◽  
Author(s):  
KIICHI NAGAYASU ◽  
HIROMITSU KOMIYAMA ◽  
SHUN ISHIYAMA ◽  
DAI OGURA ◽  
RINA TAKAHASHI ◽  
...  

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e15071-e15071
Author(s):  
H. Kuramochi ◽  
K. Hayashi ◽  
G. Nakajima ◽  
H. Kamikozuru ◽  
M. Yamamoto

e15071 Background: Oxaliplatin has been widely used for the treatment of colorectal cancer. The mechanism of action of platinum compounds such as oxaliplatin is to bind to a DNA molecule in the form of a platinum-DNA-adduct. Excision repair cross complementation group 1 (ERCC1), which plays a major role in the nucleotide excision pathway, has a polymorphism in codon 118, and is reported to be associated with a resistance to platinum-based therapy. Thymidylate synthase (TS) and dehydropyrimidine dehydrogenase (DPD) are key enzymes of 5-FU metabolism and are well known to be associated with a response to 5-FU-based therapy. Methods: Twenty-one colorectal cancer patients (male:female = 7:14; median age, 65) treated with a combination of oxaliplatin and S-1 as a first-line therapy were analyzed for ERCC1 codon 118 polymorphism and the mRNA expression levels of TS, ERCC1, and DPD. Formalin-fixed paraffin- embedded surgical specimens were used and t-RNA and DNA were extracted. The mRNA expression levels were measured using real-time RT-PCR, and the polymorphism was analyzed using the allelic discrimination method together with real-time PCR. Results: No correlation was observed between ERCC1 codon118 polymorphism and any response to the chemotherapy. ERCC1 mRNA levels tended to be higher in the patients with wild-type homozygous alleles in codon 118 than in those with at least one mutant allele(1.19 vs.0.68: p= 0.15). Patients with both high TS and ERCC1 mRNA levels showed a significantly lower response rate than the others (25% vs. 67%, p=0.02). No relationship was seen between DPD mRNA expression levels and the response. Conclusions: The mRNA expression levels of TS and ERCC1 appear to be useful markers for the treatment of S-1 and oxaliplatin. No particular usefulness of ERCC1 codon 118 polymorphism was verified. No significant financial relationships to disclose.


2015 ◽  
Vol 9 (4) ◽  
pp. 920-932 ◽  
Author(s):  
Bianca Mostert ◽  
Anieta M. Sieuwerts ◽  
Joan Bolt-de Vries ◽  
Jaco Kraan ◽  
Zarina Lalmahomed ◽  
...  

2006 ◽  
Vol 233 (1) ◽  
pp. 117-123 ◽  
Author(s):  
Mariano Monzo ◽  
Isabel Moreno ◽  
Rosa Artells ◽  
Rafael Ibeas ◽  
Alfons Navarro ◽  
...  

2010 ◽  
Vol 46 (3) ◽  
pp. 642-649 ◽  
Author(s):  
R. Artells ◽  
I. Moreno ◽  
T. Díaz ◽  
F. Martínez ◽  
B. Gel ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document